Back to discover

Protein / target

Interleukin-17A

Encoded byIL17AQ16552Homo sapiensSwiss-Prot
Clinically validated
Therapeutic maturity
3
Approved medicines
Open Targets target-level
View by indication →
30
Clinical trials
Small-molecule tractable
Druggability
Structure with Ligand

Protein at a glance

Biological role

Protein heterodimerization

Strongest disease association

Arthritis

Via encoding gene IL17A · Genetic literature evidence · score 0.61

Therapeutic position

Established drug target

Antibodies

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Effector cytokine of innate and adaptive immune system involved in antimicrobial host defense and maintenance of tissue integrity.

View complete UniProt function annotation

Effector cytokine of innate and adaptive immune system involved in antimicrobial host defense and maintenance of tissue integrity (PubMed:24120361). Signals via IL17RA-IL17RC heterodimeric receptor complex, triggering homotypic interaction of IL17RA and IL17RC chains with TRAF3IP2 adapter. This leads to downstream TRAF6-mediated activation of NF-kappa-B and MAPkinase pathways ultimately resulting in transcriptional activation of cytokines, chemokines, antimicrobial peptides and matrix metalloproteinases, with potential strong immune inflammation (PubMed:17911633, PubMed:18684971, PubMed:19825828, PubMed:21350122, PubMed:24120361, PubMed:8676080). Plays an important role in connecting T cell-mediated adaptive immunity and acute inflammatory response to destroy extracellular bacteria and fungi. As a signature effector cytokine of T-helper 17 cells (Th17), primarily induces neutrophil activation and recruitment at infection and inflammatory sites (By similarity). In airway epithelium, mediates neutrophil chemotaxis via induction of CXCL1 and CXCL5 chemokines (By similarity). In secondary lymphoid organs, contributes to germinal center formation by regulating the chemotactic response of B cells to CXCL12 and CXCL13, enhancing retention of B cells within the germinal centers, B cell somatic hypermutation rate and selection toward plasma cells (By similarity). Effector cytokine of a subset of gamma-delta T cells that functions as part of an inflammatory circuit downstream IL1B, TLR2 and IL23A-IL12B to promote neutrophil recruitment for efficient bacterial clearance (By similarity). Effector cytokine of innate immune cells including invariant natural killer cell (iNKT) and group 3 innate lymphoid cells that mediate initial neutrophilic inflammation (By similarity). Involved in the maintenance of the integrity of epithelial barriers during homeostasis and pathogen infection (PubMed:21350122). Upon acute injury, has a direct role in epithelial barrier formation by regulating OCLN localization and tight junction biogenesis (By similarity). As part of the mucosal immune response induced by commensal bacteria, enhances host's ability to resist pathogenic bacterial and fungal infections by promoting neutrophil recruitment and antimicrobial peptides release (By similarity). In synergy with IL17F, mediates the production of antimicrobial beta-defensins DEFB1, DEFB103A, and DEFB104A by mucosal epithelial cells, limiting the entry of microbes through the epithelial barriers (By similarity). Involved in antiviral host defense through various mechanisms (By similarity). Enhances immunity against West Nile virus by promoting T cell cytotoxicity (By similarity). May play a beneficial role in influenza A virus (H5N1) infection by enhancing B cell recruitment and immune response in the lung (By similarity). Contributes to influenza A virus (H1N1) clearance by driving the differentiation of B-1a B cells, providing for production of virus-specific IgM antibodies at first line of host defense (By similarity)

Subcellular location

Secreted
Domains and Gene Ontology detail (41)

Gene Ontology

  • Cexternal side of plasma membrane
  • Cextracellular region
  • Cextracellular space
  • Cplasma membrane
  • Fcytokine activity
  • Fprotein heterodimerization activity
  • Fprotein homodimerization activity
  • Papoptotic process
  • Pcell death
  • Pcell-cell signaling
  • Pdefense response to fungus
  • Pdefense response to Gram-negative bacterium

155 aa · 18 kDa

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Cell migrationUniProtImmune signallingUniProt · GOTranscriptional regulationUniProt · GOCell adhesionUniProt · GO
View supporting evidence

Cell migration

  • ·Effector cytokine of innate and adaptive immune system involved in antimicrobial host de…

Immune signalling

  • ·Effector cytokine of innate and adaptive immune system involved in antimicrobial host de…
  • ·cytokine activity
  • ·immune response
  • ·inflammatory response

Transcriptional regulation

  • ·Effector cytokine of innate and adaptive immune system involved in antimicrobial host de…
  • ·gene expression
  • ·positive regulation of transcription by RNA polymerase II

Cell adhesion

  • ·Effector cytokine of innate and adaptive immune system involved in antimicrobial host de…
  • ·positive regulation of bicellular tight junction assembly

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Approved medicines with mapped indications

2 medicines · 3 areas

Approved therapies targeting this protein, grouped by what they are approved to treat — the disease-first view of the medicines below. Relationships come from the canonical approved-indication graph (ChEMBL phase-4), the same source as the drug cards.

Immune System Diseases2 medicines
Psoriasis2 medicines
Arthritis, Psoriatic1 medicine

3 medicines meet Open Targets' target-level approved-medicine definition; the 2 shown here are those on this page with a canonical approved disease indication in the graph. Approved indications from ChEMBL (phase-4), via the canonical drug→disease graph.

Drugs targeting this protein

2

How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.

bimekizumab
Narrow target profileApprovedInhibitor

Interleukin 17A inhibitor

Indicated for Immune System Diseases, Psoriasis

Direct interaction with this protein · 1 of 2 recorded protein targets — narrow recorded profile

ixekizumab
Narrow target profileApprovedInhibitor

Interleukin 17A inhibitor

Indicated for Arthritis, Psoriatic, Immune System Diseases, Psoriasis

Direct interaction with this protein · Only this protein recorded as a target

ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene IL17A

Gene-level evidence surfaced through the gene IL17Athat encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Psoriasis
0.80Well supported

Clinical evidence dominant · Open Targets 0.63

Psoriasis vulgaris
0.74Moderately supported

Clinical evidence dominant · Open Targets 0.60

Arthritis, Psoriatic
0.74Moderately supported

Clinical evidence dominant · Open Targets 0.60

Spondylitis, Ankylosing
0.74Moderately supported

Clinical evidence dominant · Open Targets 0.60

Immune System Diseases
0.63Moderately supported

Clinical evidence dominant · Open Targets 0.51

View evidence synthesis (5)
PsoriasisWell supported
0.80
agreement 0.660.93
Clinical75%Literature15%RNA expression9%

Open Targets aggregate 0.63 · 3 independent evidence families

Psoriasis vulgarisModerately supported
0.74
agreement 0.590.90
Clinical94%Literature6%

Open Targets aggregate 0.60 · 2 independent evidence families

Arthritis, PsoriaticModerately supported
0.74
agreement 0.590.90
Clinical94%Literature6%

Open Targets aggregate 0.60 · 2 independent evidence families

Spondylitis, AnkylosingModerately supported
0.74
agreement 0.590.90
Clinical92%Literature9%

Open Targets aggregate 0.60 · 2 independent evidence families

Immune System DiseasesModerately supported
0.63
agreement 0.480.79
Clinical95%Literature5%

Open Targets aggregate 0.51 · 2 independent evidence families

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Psoriasis0.63
Psoriasis vulgaris0.60
Arthritis, Psoriatic0.60
Spondylitis, Ankylosing0.60
Immune System Diseases0.51
Hidradenitis Suppurativa0.41
Arthritis, Rheumatoid0.40
Arthritis0.40

Drug development

11 compounds recorded · 3 approved · 8 in clinical development

Open Targets' development universe — every compound recorded against the target at any stage, not all approved medicines. Distinct from the 2 drugs that target this protein in Forefront's canonical graph (2 with a mapped approved indication, shown above): these count different sets and are not a subset relation.

View all recorded compounds (10)
PERAKIZUMABPhase 1
TIBULIZUMABPhase 2 3
M-1095Phase 3
REMTOLUMABPhase 2
IXEKIZUMABApproval
SECUKINUMABApproval
BIMEKIZUMABApproval
AFASEVIKUMABPhase 1
VUNAKIZUMABPhase 3
IZOKIBEPPhase 3

Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.

Tractability

Small moleculesEmerging

Feasibility evidence (structure with ligand and high-quality ligand) — no clinical-stage drug of this modality recorded.

AntibodiesStrong

Approved Drug and UniProt loc high conf support this modality.

Protein degradersEmerging

Feasibility evidence (small molecule binder) — no clinical-stage drug of this modality recorded.

Other modalitiesStrong

Advanced Clinical support this modality.

View underlying tractability evidence (8)
SM · Structure with LigandSM · High-Quality LigandAB · Approved DrugAB · UniProt loc high confAB · GO CC high confAB · UniProt SigP or TMHMMPR · Small Molecule BinderOC · Advanced Clinical

Raw Open Targets tractability assessment buckets, by modality.

Clinical trials

30

Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.

View all trials (26)

UNKNOWN · via ixekizumab · NCT06374979

ClinicalTrials.gov via the drug-target graph.

What's happening now

12

Recent therapeutic activity around this target — regulatory actions, clinical trials and safety signals for 2 drugs that target this protein, plus publications where such a drug is a genuine subject. Every item is reached indirectly through the drug, not the protein itself; incidental mentions (a paper that merely measures a drug) and press items are excluded.

  1. Trial status changed2026-08-07

    A Multicenter, Randomized, Parallel-Group, Double-Blind, Active-Controlled Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis

    Status changed to Active, not recruiting · ClinicalTrials.gov · via bimekizumab

  2. New publication2026-05-01
    Bimekizumab safety and efficacy in patients with psoriatic arthritis: 3-year results from two phase 3 studies.

    Rheumatology (Oxford, England) · 2026 · Europe PMC · via bimekizumab

  3. New publication2026-03-09
    Bimekizumab efficacy in scalp, nail and palmoplantar psoriasis versus comparators and over 4 years.

    The Journal of dermatological treatment · 2026 · Europe PMC · via bimekizumab

  4. New publication2026-02-12
    Bimekizumab efficacy and safety in Chinese patients with psoriasis in the BE SHINING Phase 3 study.

    Journal of the European Academy of Dermatology and Venereology : JEADV · 2026 · 1 citation · Europe PMC · via bimekizumab

  5. New publication2025-11-15
    Bimekizumab demonstrated a favorable safety profile and high levels of efficacy with up to 2 years of treatment in patients with moderate to severe hidradenitis suppurativa: Pooled results from two phase 3 randomized, controlled trials and their open-label extension.

    Journal of the American Academy of Dermatology · 2026 · 1 citation · Europe PMC · via bimekizumab

  6. New publication2025-10-22
    Sustained resolution of enthesitis and peripheral arthritis over 104 weeks with bimekizumab in axial spondyloarthritis.

    RMD open · 2025 · 2 citations · Europe PMC · via bimekizumab

  7. New publication2025-06-01
    Psychometric validation and interpretation thresholds of the Hidradenitis Suppurativa Quality of Life (HiSQOL©) questionnaire using pooled data from the phase III BE HEARD I & II trials of bimekizumab in hidradenitis suppurativa.

    The British journal of dermatology · 2025 · 1 citation · Europe PMC · via bimekizumab

  8. New publication2024-09-27
    Bimekizumab efficacy and safety in Korean patients with moderate to severe plaque psoriasis: A phase 3, randomized, placebo-controlled, double-blinded study.

    The Journal of dermatology · 2024 · 1 citation · Europe PMC · via bimekizumab

  9. New publication2024-09-01
    Effect of bimekizumab on patient-reported disease impact in patients with psoriatic arthritis: 1-year results from two phase 3 studies.

    Rheumatology (Oxford, England) · 2024 · 6 citations · Europe PMC · via bimekizumab

  10. New publication2024-06-04
    Improved physical functioning, sleep, work productivity and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: results from two phase 3 studies.

    RMD open · 2024 · 7 citations · Europe PMC · via bimekizumab

  11. Regulatory approval2021-08-20

    Approval: Bimzelx (EMA)

    ema · regulatory · ema · via bimekizumab

  12. Regulatory approval2016-04-25

    Approval: Taltz (EMA)

    ema · regulatory · ema · via ixekizumab

Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.